Cargando…

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

OBJECTIVE: Second-generation antipsychotics (SGAs) have a high risk of causing metabolic syndrome (MetS). There is accumulating evidence supporting the fact that the activation of inflammatory pathway contributes to the development of MetS and further aggravates cognitive impairment. This study aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Xinyu, Wang, Yewei, Chen, Yan, Ren, Juanjuan, Zhang, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681158/ https://www.ncbi.nlm.nih.gov/pubmed/31534339 http://dx.doi.org/10.2147/NDT.S202159

Ejemplares similares

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy
por: Fang, Xinyu, et al.
Publicado: (2020)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
por: Jaberi, Nayyer, et al.
Publicado: (2020)

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics
por: Rice, Jessie, et al.
Publicado: (2020)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients
por: Chadda, Rakesh K., et al.
Publicado: (2013)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

Differences in inflammatory marker profiles and cognitive functioning between deficit and nondeficit schizophrenia
por: Wang, Dandan, et al.
Publicado: (2022)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
por: Mahmoud, Ahmed, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
por: Sneller, Marius H., et al.
Publicado: (2021)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Yeh, Tzu-Pei, et al.
Publicado: (2021)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
por: Rognoni, Carla, et al.
Publicado: (2021)

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
por: Abo Alrob, Osama, et al.
Publicado: (2019)

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
por: Grajales, Diana, et al.
Publicado: (2019)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics
por: Naderyan Fe'li, Shadi, et al.
Publicado: (2019)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
por: Shi, Lizheng, et al.
Publicado: (2009)

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
por: Kearns, Benjamin, et al.
Publicado: (2021)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu, Xiaoli, et al.
Publicado: (2014)

Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis
por: Chen, Yan, et al.
Publicado: (2020)

Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study
por: Rohatgi, Rupali, et al.
Publicado: (2018)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics
por: Kang, Seung-Gul, et al.
Publicado: (2021)

Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
por: Krill, Rebecca A, et al.
Publicado: (2014)

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
por: Hirsch, Lauren, et al.
Publicado: (2018)

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?
por: Venkatasubramanian, Ganesan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3l7feu9tju7re2q6sdp8h0ftc6